“The first primary end point was the efficacy of BNT162b2 against confirmed Covid-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose; the second primary end point was efficacy in participants with and participants without evidence of prior infection…
Major secondary end points included the efficacy of BNT162b2 against severe Covid-19.”
Note: Efficacy against SARS-CoV-2 transmission/infection and COVID-19 mortality were not endpoints (i.e., tested outcomes).
© 2023 Massachusetts Medical Society. All rights reserved. Reuse of Content Within a Thesis or Dissertation Content (full-text or portions thereof) may be used in print and electronic versions of a dissertation or thesis without formal permission from the Massachusetts Medical Society (MMS), Publisher of the New England Journal of Medicine. The following credit line must be printed along with the copyrighted material: Reproduced with permission from (scientific reference citation), Copyright Massachusetts Medical Society. Source: https://www.nejm.org/about-nejm/permissions